Research
Hormonal
Among GLP-1RAs, Dulaglutide has the lowest risk of causing intolerable gastrointestinal adverse reactions, while Semaglutide and Liraglutide have the highest risk.
If you are experiencing intolerable gastrointestinal side effects on one GLP-1RA (like Semaglutide or Liraglutide), switching to Dulaglutide may reduce these side effects, as it has the lowest risk of intolerable GI reactions among the studied agents.
GoodSupportsHIGH confidence
The results of STEP2 showed that Dulaglutide had the lowest risk of intolerable GI AEs. Significantly, Liraglutide and Semaglutide have similar SUCRAs... Liraglutide (87.7) ranked first, followed by Semaglutide (85.8)... Dulaglutide (52.7).
Why this rating
Based on network meta-analysis of 64 RCTs.
Source
GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
Ziqi Zhang et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1149328
Meta-analysis · 64 studiesCited 38×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) cause a significantly higher rate of intolerable gastrointestinal adverse reactions leading to drug withdrawal compared to other hypoglycemic agents (Insulin, SGLT2i, DPP4i, TZD) and placebo.Good
- For Semaglutide, higher doses are associated with a higher risk of intolerable gastrointestinal adverse reactions.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →